Volume 74, Number 23, June 8, 2010
About this course
- Released: 06/07/2010
- Expires: 06/08/2012
Learning Objectives:
Upon completion of the article by Naismith et al., the participant should be able to:
· Briefly state the mechanism of action of rituximab as an immunosuppressive agent.
· Discuss the methods used in this study to assess efficacy of rituximab in multiple sclerosis.
· Discuss the findings from this study assessing rituximab as add-on therapy for multiple sclerosis.
Core Competencies:
The article by Naismith et al. covers the following core competency:
· Medical Knowledge
Learning Objectives:
Upon completion of the article by Wijdicks et al., the participant should be able to:
· Discuss the findings from this practice parameter regarding any updates to the recommendations of the 1995 AAN practice parameter on the diagnosis of brain death in adults.
· Discuss whether there are any published reports of recovery of neurologic function after a diagnosis of brain death using the criteria of the 1995 AAN practice parameter.
· State the recommendations from the authors of this study regarding the steps that should be performed and documented when determining brain death in adults.
Core Competencies:
The article by Wijdicks et al. covers the following core competency:
· Medical Knowledge
Author Disclosures
Refer to Information and Author section available in the Tool Bar for each article.
THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES
ACCREDITATION STATEMENT
The American Academy of Neurology designates that participants will receive 1.5 AMA PRA Category 1 CME credits if both CME courses for the issue are completed. Physicians should only claim credit commensurate with the extent of their participation in the activity. The American Academy of Neurology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MISSION STATEMENT/PROGRAM OBJECTIVES
After evaluating a specific article published in Neurology, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.
PARTICIPANTS
This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.
CREDITS
The American Academy of Neurology designates that participants will receive 1.5 AMA PRA Category 1 CME credits if both CME courses for the issue are completed.
The American Academy of Neurology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.
DISCLOSURES
Steven Lewis, MD, has received personal compensation in an editorial capacity for the National Board of Medical Examiners and the American College of Physicians; Paul Schulz, MD, has received personal compensation for activities with Pfizer.
COMMERCIAL SUPPORT
This CME program receives no commercial support.
